Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates

Kevin O. Saunders, Sampa Santra, Robert Parks, Nicole L. Yates, Laura L. Sutherland, Richard M. Scearce, Harikrishnan Balachandran, Todd Bradley, Derrick Goodman, Amanda Eaton, Sherry A. Stanfield-Oakley, James Tartaglia, Sanjay Phogat, Giuseppe Pantaleo, Mariano Esteban, Carmen E. Gomez, Beatriz Perdiguero, Bertram Jacobs, Karen Kibler, Bette KorberDavid C. Montefiori, Guido Ferrari, Nathan Vandergrift, Hua Xin Liao, Georgia D. Tomaras, Barton F. Haynes

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strategy to eradicate AIDS. A critical question is whether antibodies that do not neutralize primary isolate (tier 2) HIV-1 strains can protect from infection. In this study, we investigated the ability of an attenuated poxvirus vector (NYVAC) prime-envelope gp120 boost to elicit potentially protective antibody responses in a rhesus macaque model of mucosal simian-human immunodeficiency virus (SHIV) infection. NYVAC vector delivery of a group M consensus envelope, trivalent mosaic envelopes, or a natural clade B isolate B.1059 envelope elicited antibodies that mediated neutralization of tier 1 viruses, cellular cytotoxicity, and phagocytosis. None of the macaques made neutralizing antibodies against the tier 2 SHIV SF162P3 used for mucosal challenge. Significant protection from infection was not observed for the three groups of vaccinated macaques compared to unvaccinated macaques, although binding antibody to HIV-1 Env correlated with decreased viremia after challenge. Thus, NYVAC Env prime-gp120 boost vaccination elicited polyfunctional, nonneutralizing antibody responses with minimal protective activity against tier 2 SHIV mucosal challenge.

Original languageEnglish (US)
Article numbere02035-17
JournalJournal of virology
Volume92
Issue number8
DOIs
StatePublished - Apr 1 2018

    Fingerprint

Keywords

  • HIV
  • HIV vaccine
  • Neutralizing antibodies
  • Simian-human immunodeficiency virus

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Saunders, K. O., Santra, S., Parks, R., Yates, N. L., Sutherland, L. L., Scearce, R. M., Balachandran, H., Bradley, T., Goodman, D., Eaton, A., Stanfield-Oakley, S. A., Tartaglia, J., Phogat, S., Pantaleo, G., Esteban, M., Gomez, C. E., Perdiguero, B., Jacobs, B., Kibler, K., ... Haynes, B. F. (2018). Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates. Journal of virology, 92(8), [e02035-17]. https://doi.org/10.1128/JVI.02035-17